Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + xentuzumab
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Abemaciclib + xentuzumab is a combination therapy consisting of abemaciclib, a CDK4/6 inhibitor, and xentuzumab, an insulin-like growth factor (IGF) ligand-neutralizing antibody. This combination targets two complementary pathways involved in cancer cell proliferation. Abemaciclib disrupts cell cycle progression by inhibiting CDK4/6, while xentuzumab neutralizes IGF ligands, preventing activation of the IGF pathway which leads to increased cyclin D1 expression. The dual inhibition approach aims to enhance anti-tumor efficacy, particularly in hormone receptor-positive (HR+), HER2-negative breast cancer.
- Other names
- xentuzumab + abemaciclib
02
Targets
CDK1 (Cyclin-dependent kinase 1)Cyclin-dependent kinase 2–cyclin A or E complexCDK5 (Cyclin-dependent kinase 5)Cyclin-dependent kinase 6–cyclin D1 complexP-TEFb (Positive transcription elongation factor b)IGF-1 (Insulin-like growth factor 1)IGF2 (Insulin-like growth factor 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on abemaciclib + xentuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + xentuzumab.